Skip to content
Open access

Pediatric-onset multiple sclerosis in Finland.

Sep 2026 · European journal of paediatric neurology · Vol 65, pp. 15-20 · 0 citations · 41 references
Medicine

TL;DR

POMS is rare in Finland, and although ON was seen in 32% of all cases of CIS, other mono- and multifocal manifestations predominated in those who developed POMS.

Abstract

INTRODUCTION Although there are extensive data on multiple sclerosis (MS) in adults, the epidemiology and clinical features of pediatric-onset multiple sclerosis (POMS) in Finland are unknown. SUBJECTS and methods: Individuals under 18 years of age diagnosed with clinically isolated syndrome (CIS) or MS were identified from the MS registries of Tampere and Helsinki University Hospitals, based on the ICD-10 classification. The data were extracted from the electronic patient records (EPRs) and MS registries.

Results

A total of 73 children with CIS were identified. Among these, 34 (47%) were diagnosed with MS before the age of 18, and an additional 8 (11%) by the age of 28. The median time from CIS to a diagnosis of MS in those diagnosed before 18 was 6 months. CIS phenotypes included optic neuritis (ON) in 23/73 (32%), acute disseminated encephalomyelitis (ADEM) in 10/73 (14%), transverse myelitis (TM) in 9/73 (12%), internuclear ophthalmoplegia (INO) in 5/73 (7%) and other or undefined monofocal presentations in 15/73 (21%) and multifocal presentations in 11/73 (15%). The prevalence of POMS in our cohort was 5.5 per 100,000, with an incidence ranging from 0.16 to 0.81 per 100,000.

Conclusion

POMS is rare in Finland. Although ON was seen in 32% of all cases of CIS, other mono- and multifocal manifestations predominated in those who developed POMS. Unlike in adults, ADEM can also rarely develop into MS in pediatric patients.

Read PDF

Similar papers

Open access Sep 2026

Late-onset versus adult-onset multiple sclerosis: A comparative analysis of clinical, radiological, and confirmed disability progression.

Patients with LOMS tend to have a higher prevalence of PPMS, a greater burden of comorbidities, higher baseline disability, lower relapse activity, and a shorter time to CDP.

A. Fouad, Abdallah Saad, Hadeer Mohamed Abd El-Aziz et al. · 0 citations
Review Open access Oct 2026

Association of Diagnosis Age with Clinical Characteristics and MRI Findings in Multiple Sclerosis

Background: Age at multiple sclerosis (MS) diagnosis may be associated with clinical course, inflammatory activity, and disability accrual, but evidence across the full age spectrum remains limited. We compared clinical and radiological features, phenotype distribution, and time to first post-diagnosis relapse across e...

O. Mirmosayyeb, Sepehr Aghajanian, Fatemeh Mohammadifard et al. · 0 citations
Review Sep 2026

Pediatric multiple sclerosis: a diagnostic overview and the importance of early identification

This review summarizes the diagnostic work-up of children with a first acquired demyelinating syndrome, differential diagnosis, the role of MRI, cerebrospinal fluid (CSF) markers, antibody testing, serum neurofilament light chain, optical pathway assessment and the 2024 McDonald criteria.

M. Margoni, Massimo Filippi, M. Rocca · 0 citations
Open access Sep 2026

Distinct clinical phenotypes of late onset and early onset epilepsies.

OBJECTIVE Despite representing the most common and fastest growing form of epilepsy in older adults, the clinical features of late onset epilepsy (LOE) and how it differs from early onset epilepsy (EOE) remain largely underexplored. Therefore, we evaluate the characteristics and risk factors of LOE compared to EOE. M...

Syeda Amrah Hashmi, Mark Quigg, M. Abbas et al. · 0 citations
Review Open access Sep 2026

Pediatric-Onset Multiple Sclerosis in the Gulf: A Scoping Review of the Current Evidence Base and Research Gaps

The Gulf POMS evidence base is real but narrow, concentrated, and heterogeneous; a scoping review is currently the more informative synthesis than a quantitative meta-analysis, which supports a harmonized, multi-country Gulf pediatric MS registry with standardized outcome reporting, including neurocognitive and quality...

E. Shosha, N. Qadi, Rakan S. Alromayan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.